13F Filings History of Takeda Pharmaceutical Co Ltd

Latest 13F report
Q3 2025 - Nov 13, 2025
Value $
$16.4M
Signature - Title
Max Heuer - Authorized Signatory
Location
Tokyo, Japan
Summary
This page shows a list of all the recent 13F filings made by Takeda Pharmaceutical Co Ltd. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Takeda Pharmaceutical Co Ltd reported 8 stock holdings with total value $16.4M as of Q3 2025. Top holdings included OVID, EQ, XLO, STTK, and LYEL.

Notify me when Takeda Pharmaceutical Co Ltd files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2025 8 $16.4M +$223K -$13.9M -$13.7M OVID, EQ, XLO, STTK, LYEL 13F-HR 11/13/2025, 07:57 AM
Q2 2025 11 $19.6M $0 -$6.91M -$6.91M HLVX, OVID, XLO, AMWL, EQ 13F-HR 8/7/2025, 08:51 PM
Q1 2025 11 $16.2M $0 $0 HLVX, OVID, XLO, EQ, AMWL 13F-HR 5/12/2025, 06:19 AM
Q4 2024 11 $26.6M +$906K -$11M -$10.1M HLVX, OVID, XLO, EQ, STTK 13F-HR 2/12/2025, 08:06 AM
Q3 2024 10 $38M $0 -$128M -$128M HLVX, WVE, OVID, STTK, EQ 13F-HR 2/13/2025, 06:40 AM
Q2 2024 13 $232M $0 -$22.5M -$22.5M DNLI, HLVX, PHAT, WVE, OVID 13F-HR 2/13/2025, 06:33 AM
Q1 2024 15 $289M +$1.42M -$51M -$49.6M HLVX, DNLI, PHAT, OVID, STTK 13F-HR 2/13/2025, 06:28 AM
Q4 2023 14 $327M $0 $0 HLVX, DNLI, PHAT, OVID, STTK 13F-HR 2/13/2025, 06:13 AM